A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TAB006, as Monotherapy and in Combination With Toripalimab, in Patients With Previously Treated, Advanced Malignancies
Latest Information Update: 01 Jun 2022
At a glance
- Drugs CHS 006 (Primary) ; Toripalimab (Primary)
- Indications Cancer; Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Shanghai Junshi Biosciences
- 24 May 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 15 Feb 2022 Status changed from planning to not yet recruiting.
- 05 Feb 2021 New trial record